Meeting
2017 ASCO Annual Meeting
Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.
Authors
Koichi Takahashi
The University of Texas MD Anderson Cancer Center, Houston, TX
Koichi Takahashi , Yasmin Abaza , Ehab L. Atallah , Bruno C. Medeiros , Sam Khal , Martha Lucia Arellano , Mrinal Patnaik , Richard Ghalie , Guillermo Garcia-Manero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01912274
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7034)
DOI
10.1200/JCO.2017.35.15_suppl.7034
Abstract #
7034
Poster Bd #
234
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.
First Author: Maha AT Elsebaie
Poster
2022 ASCO Annual Meeting
Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.
First Author: Farhad Ravandi
Poster
2022 ASCO Annual Meeting
Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
First Author: Stéphane De Botton
Poster
2022 ASCO Annual Meeting
Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real-world data.
First Author: Taylor J. Jensen